|
Volumn 4, Issue 6, 2012, Pages 648-652
|
IBC's 23rd antibody engineering and 10th antibody therapeutics conferences, and the Annual Meeting of the Antibody Society: December 2-6, 2012, San Diego, CA
|
Author keywords
Antibody engineering; Antibody therapeutics; Antibody drug conjugates; Bispecific antibodies; Intellectual property law
|
Indexed keywords
BAVITUXIMAB;
BEVACIZUMAB;
BRENTUXIMAB VEDOTIN;
CD47 ANTIGEN;
CETUXIMAB;
IMMUNOMODULATING AGENT;
IPILIMUMAB;
MONOCLONAL ANTIBODY;
PANITUMUMAB;
RECOMBINANT ANTIBODY;
RECOMBINANT CYTOKINE;
RITUXIMAB;
TRASTUZUMAB;
VEDOLIZUMAB;
ANTIBODY ENGINEERING;
ANTIBODY SPECIFICITY;
ANTIGEN BINDING;
ANTINEOPLASTIC ACTIVITY;
B LYMPHOCYTE;
BLOOD BRAIN BARRIER;
CENTRAL NERVOUS SYSTEM;
CONFERENCE PAPER;
CROHN DISEASE;
DNA SEQUENCE;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG SAFETY;
ENTERITIS;
HUMAN;
IMMUNE RESPONSE;
IMMUNOMODULATION;
IMMUNOREACTIVITY;
KIDNEY CANCER;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MULTIPLE SCLEROSIS;
NEOPLASM;
NONHUMAN;
RHEUMATOID ARTHRITIS;
ANTIBODY ENGINEERING;
ANTIBODY THERAPEUTICS;
ANTIBODY-DRUG CONJUGATES;
BISPECIFIC ANTIBODIES;
INTELLECTUAL PROPERTY LAW;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
CALIFORNIA;
HUMANS;
IMMUNOTHERAPY;
IMMUNOTOXINS;
PROTEIN ENGINEERING;
SOCIETIES, SCIENTIFIC;
TRANSLATIONAL MEDICAL RESEARCH;
|
EID: 84869764284
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.22221 Document Type: Conference Paper |
Times cited : (1)
|
References (0)
|